New pill shows promise in early lung cancer trial

NCT ID NCT06905197

Recruiting now Disease control Sponsor: Dizal Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new daily pill called DZD6008 in 140 people with advanced non-small cell lung cancer that has certain EGFR mutations. The main goals are to check the drug's safety and see if it can shrink tumors. Participants will take DZD6008 by mouth every day, and some may also receive another drug called sunvozertinib.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DZD6008 (a drug taken daily by mouth)
What this could lead to: If this works, it could point toward a new treatment option for people with advanced lung cancer that has specific EGFR mutations.
What could go wrong: This is a very early phase 1 trial, so the drug may not be effective or could have unexpected side effects. It is small and focused on safety, not proof of a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Blacktown Hospital
ACTIVE_NOT_RECRUITING

Blacktown, New South Wales, 2148, Australia
Chris O'Brien Lifehouse
NOT_YET_RECRUITING

Camperdown, New South Wales, 2050, Australia
Herbert Irving Comprehensive Cancer Center
RECRUITING

New York, New York, 10032, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
RECRUITING

New York, New York, 10016, United States
Virginia Cancer Specialist (NEXT Oncology-Virginia)
ACTIVE_NOT_RECRUITING

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.